Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Aug
27
Today In Oncology
Cleveland Clinic President Discusses AI Summit for Health-Care Professionals
Dr. Gary R. Morrow, a Pioneer in Cancer Research, Dies at 82
FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer
ASCO Remembers Supportive Care and Symptom Management Pioneer Gary R. Morrow, PhD, MS
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo